<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Addex Therapeutics Ltd — News on 6ix</title>
    <link>https://6ix.com/company/addex-therapeutics-ltd</link>
    <description>Latest news and press releases for Addex Therapeutics Ltd on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Apr 2026 05:00:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/addex-therapeutics-ltd" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68361aad78dffbe2df13edd7.webp</url>
      <title>Addex Therapeutics Ltd</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd</link>
    </image>
    <item>
      <title>Addex GABAB PAM Candidate Demonstrates Solid Anti-Tussive Activity in Bleomycin IPF-Related Chronic Cough Model</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-gabab-pam-candidate-demonstrates-solid-anti-tussive-activity-in-bleomycin-ipf-related-chronic-cough-model</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-gabab-pam-candidate-demonstrates-solid-anti-tussive-activity-in-bleomycin-ipf-related-chronic-cough-model</guid>
      <pubDate>Wed, 29 Apr 2026 05:00:00 GMT</pubDate>
      <description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 29, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today encouraging preclinical data demonstrating antitussive activity of its GABAB positive allosteric modulator (PAM) candidate in a bleomycin (BLM)-induced idiopathic pulmonary fibrosis (IPF) exacerbated chr</description>
    </item>
    <item>
      <title>Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-spin-out-company-neurosterix-on-track-to-complete-phase-1-clinical-study-of-ntx-253-for-schizophrenia-in-q2-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-spin-out-company-neurosterix-on-track-to-complete-phase-1-clinical-study-of-ntx-253-for-schizophrenia-in-q2-2026</guid>
      <pubDate>Thu, 23 Apr 2026 05:00:00 GMT</pubDate>
      <description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, is on track to complete its Phase 1 clinical study evaluating NTX-253 in Q2 2026. NTX-253 is an investigational potent, selective, orally available positive allost</description>
    </item>
    <item>
      <title>Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Non-Human Primate Chronic Cough Model</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-gabab-pam-candidate-demonstrates-robust-anti-tussive-activity-in-non-human-primate-chronic-cough-model</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-gabab-pam-candidate-demonstrates-robust-anti-tussive-activity-in-non-human-primate-chronic-cough-model</guid>
      <pubDate>Tue, 21 Apr 2026 05:00:00 GMT</pubDate>
      <description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 21, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in a non-human primate (NHP) chronic cough model. “These important data i</description>
    </item>
    <item>
      <title>Addex Announces Publication of Preclinical Data Supporting Potential of mGlu7 Negative Allosteric Modulators to Transform Anxiety and Fear-Related Disorder Treatment</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-announces-publication-of-preclinical-data-supporting-potential-of-mglu7-negative-allosteric-modulators-to-transform-anxiety-and-fear-related-disorder-treatment</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-announces-publication-of-preclinical-data-supporting-potential-of-mglu7-negative-allosteric-modulators-to-transform-anxiety-and-fear-related-disorder-treatment</guid>
      <pubDate>Tue, 03 Feb 2026 06:00:00 GMT</pubDate>
      <description>Data published in Molecular Psychiatry Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, February 3, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today publication of data in Molecular Psychiatry1 demonstrating that targeting metabotropic glutamate receptor 7 (mGlu7) with negative allosteric modulators (NAM) coul</description>
    </item>
    <item>
      <title>Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with  M4 PAM - NTX-253 for Schizophrenia</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-spin-neurosterix-started-phase-060000980</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-spin-neurosterix-started-phase-060000980</guid>
      <pubDate>Wed, 07 Jan 2026 06:00:00 GMT</pubDate>
      <description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, January 7, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that its spin-out company, Neurosterix, has started a Phase 1 clinical study of NTX-253. NTX-253 is a potent, selective, orally available positive allosteric modulator (PAM) of the muscarinic M4 recepto</description>
    </item>
    <item>
      <title>Addex Amends its at the Market Offering Agreement With H.C. Wainwright &amp; Co.</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-amends-its-at-the-market-offering-agreement-with-hc-wainwright-and-co</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-amends-its-at-the-market-offering-agreement-with-hc-wainwright-and-co</guid>
      <pubDate>Thu, 11 Dec 2025 06:00:00 GMT</pubDate>
      <description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 11, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it has amended its At The Market Offering Agreement (the “ATM Agreement”) with H.C. Wainwright &amp; Co., LLC (“H.C. Wainwright &amp; Co.”) initially entered into on January 30, 2024. The at-the-market offerin</description>
    </item>
    <item>
      <title>Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-therapeutics-reports-2025-third-quarter-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-therapeutics-reports-2025-third-quarter-financial-results-and-provides-corporate-update</guid>
      <pubDate>Thu, 04 Dec 2025 06:00:00 GMT</pubDate>
      <description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, December 4, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today reported its financial results for the three-month and nine-month periods ended September 30, 2025, and provided a corporate update. “We continue to make great progress with our GABAB positive allosteric modulator (PA</description>
    </item>
    <item>
      <title>Addex Therapeutics to Report 2025 Third Quarter Financial Results  And Host Conference Call on December 4, 2025</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-therapeutics-to-report-2025-third-quarter-financial-results-and-host-conference-call-on-december-4-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-therapeutics-to-report-2025-third-quarter-financial-results-and-host-conference-call-on-december-4-2025</guid>
      <pubDate>Mon, 01 Dec 2025 06:00:00 GMT</pubDate>
      <description>Geneva, Switzerland, December 1, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Third Quarter 2025 Financial Results on December 4, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and</description>
    </item>
    <item>
      <title>Addex Increases Issued Share Capital to Create Treasury Shares</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-increases-issued-share-capital-to-create-treasury-shares</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-increases-issued-share-capital-to-create-treasury-shares</guid>
      <pubDate>Wed, 29 Oct 2025 06:00:00 GMT</pubDate>
      <description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, October 29, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that 34,300,000 new registered shares at a nominal value of CHF 0.01 have been issued and fully subscribed by Addex Pharma S.A, its 100% wholly-owned subsidiary. The new shares, issued from the Company</description>
    </item>
    <item>
      <title>Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-therapeutics-reports-2025-half-year-and-second-quarter-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-therapeutics-reports-2025-half-year-and-second-quarter-financial-results-and-provides-corporate-update</guid>
      <pubDate>Tue, 30 Sep 2025 05:00:00 GMT</pubDate>
      <description>Cash position of CHF 2.3 million at end of H1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recoveryInvested in Stalicla SA, confirming commitment to advancing in</description>
    </item>
    <item>
      <title>Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-therapeutics-to-report-2025-half-year-and-second-quarter-financial-results-on-september-30-2025-and-host-conference-call-on-october-1-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-therapeutics-to-report-2025-half-year-and-second-quarter-financial-results-on-september-30-2025-and-host-conference-call-on-october-1-2025</guid>
      <pubDate>Fri, 26 Sep 2025 05:00:00 GMT</pubDate>
      <description>Geneva, Switzerland, September 26, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a</description>
    </item>
    <item>
      <title>Addex Appoints Bank of New York Mellon as Depositary Bank</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-appoints-bank-of-new-york-mellon-as-depositary-bank</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-appoints-bank-of-new-york-mellon-as-depositary-bank</guid>
      <pubDate>Tue, 23 Sep 2025 05:00:00 GMT</pubDate>
      <description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 23, 2025 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced the appointment the Bank of New-York Mellon (BNY) as its new ADS depositary agent. This change is expected to become effective on October 6, 2025. The appointment of BNY has no impact on the fees paid by A</description>
    </item>
    <item>
      <title>Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-leads-chf-2-million-investment-in-stalicla-to-advance-precision-medicine-in-neuropsychiatric-disorders</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-leads-chf-2-million-investment-in-stalicla-to-advance-precision-medicine-in-neuropsychiatric-disorders</guid>
      <pubDate>Mon, 30 Jun 2025 05:00:00 GMT</pubDate>
      <description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland – June 30, 2025 – Addex Therapeutics (SIX: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced it has led a CHF 2 million investment in Stalicla, a clinical-stage company focused on precision medicine for neurodevelopmental and neuropsychiatric disorders. Stalicla will use the financing to advance its portfolio of</description>
    </item>
    <item>
      <title>Addex Shareholders Approve All Resolutions at Annual General Meeting</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-shareholders-approve-all-resolutions-at-annual-general-meeting</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-shareholders-approve-all-resolutions-at-annual-general-meeting</guid>
      <pubDate>Wed, 25 Jun 2025 05:00:00 GMT</pubDate>
      <description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that its shareholders approved, with a large majority, all proposals of the board of directors in its 2025 Annual General Meeting (AGM). The votes represented 30.18% of the company&apos;s outstanding capital. Addex shareholders approved the 2024 ann</description>
    </item>
    <item>
      <title>Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-therapeutics-reports-q1-2025-financial-results-and-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-therapeutics-reports-q1-2025-financial-results-and-provides-corporate-update</guid>
      <pubDate>Thu, 19 Jun 2025 05:00:00 GMT</pubDate>
      <description>Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior advanced GABAB PAM Substance use disorders program successfully through IND enabling studiesEntered option agreement with Sinntaxis for an exclusive license to intellectual property covering the use of mGlu5 NAM in brain injury recovery Ad Hoc Announcement Pursuant to Art. 53 LR Genev</description>
    </item>
    <item>
      <title>Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-therapeutics-to-release-q1-2025-financial-results-and-host-conference-call-on-june-19-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-therapeutics-to-release-q1-2025-financial-results-and-host-conference-call-on-june-19-2025</guid>
      <pubDate>Wed, 18 Jun 2025 05:00:00 GMT</pubDate>
      <description>Geneva, Switzerland, June 18, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will issue its Q1 2025 Financial Results on June 19, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors</description>
    </item>
    <item>
      <title>Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-gabab-pam-candidate-demonstrates-robust-anti-tussive-activity-in-multiple-chronic-cough-preclinical-models</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-gabab-pam-candidate-demonstrates-robust-anti-tussive-activity-in-multiple-chronic-cough-preclinical-models</guid>
      <pubDate>Fri, 06 Jun 2025 05:00:00 GMT</pubDate>
      <description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 6, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today robust anti-tussive activity of its novel gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) in multiple preclinical models of chronic cough compared to reference drugs</description>
    </item>
    <item>
      <title>Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-to-present-positive-gabab-pam-chronic-cough-data-at-the-10th-american-cough-conference</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-to-present-positive-gabab-pam-chronic-cough-data-at-the-10th-american-cough-conference</guid>
      <pubDate>Thu, 05 Jun 2025 05:00:00 GMT</pubDate>
      <description>Geneva, Switzerland, June 5, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that preclinical data from its gamma-aminobutyric acid sub-type B receptor (GABAB) positive allosteric modulator (PAM) cough program will be presented at the 10th American Cough Conference (June 6-7) in Dulles, VA. A presentation given by Mikhail Kalinichev,</description>
    </item>
    <item>
      <title>Addex Convenes Annual General Meeting 2025</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-convenes-annual-general-meeting-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-convenes-annual-general-meeting-2025</guid>
      <pubDate>Tue, 03 Jun 2025 05:00:00 GMT</pubDate>
      <description>Geneva, Switzerland, June 3, 2025 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today that its 2025 Annual General Meeting will take place on Tuesday June 24, 2025, at 11:00 am CEST at the Campus Biotech, Chemin des Mines 9, 1202 Geneva (doors open at 10:30 am). Agenda 1. Approval of the Annual Report, the Annual Financial Statement</description>
    </item>
    <item>
      <title>Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies</title>
      <link>https://6ix.com/company/addex-therapeutics-ltd/news/addex-partner-indivior-advances-gabab-positive-allosteric-modulator-program-successfully-through-ind-enabling-studies</link>
      <guid isPermaLink="true">https://6ix.com/company/addex-therapeutics-ltd/news/addex-partner-indivior-advances-gabab-positive-allosteric-modulator-program-successfully-through-ind-enabling-studies</guid>
      <pubDate>Mon, 12 May 2025 05:00:00 GMT</pubDate>
      <description>Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 12, 2025 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, announced today partner Indivior has successfully advanced its GABAB positive allosteric modulator (PAM) program through IND enabling studies. This is the final preclinical development stage before clinical studies can be started.</description>
    </item>
  </channel>
</rss>